Cytokinetics Inc (CYTK)
Operating return on assets (Operating ROA)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating income (ttm) | US$ in thousands | -536,248 | -524,626 | -506,090 | -497,967 | -496,205 | -495,817 | -481,993 | -370,818 | -324,202 | -218,876 | -179,636 | -223,559 | -186,313 | -201,016 | -126,631 | -104,192 | -93,943 | -81,242 | -110,353 | -104,711 |
| Total assets | US$ in thousands | 1,401,670 | 1,436,060 | 1,523,790 | 808,082 | 824,316 | 740,614 | 779,899 | 889,815 | 1,014,780 | 1,075,960 | 771,717 | 856,253 | 841,319 | 827,539 | 564,302 | 577,062 | 533,803 | 474,112 | 232,495 | 256,582 |
| Operating ROA | -38.26% | -36.53% | -33.21% | -61.62% | -60.20% | -66.95% | -61.80% | -41.67% | -31.95% | -20.34% | -23.28% | -26.11% | -22.15% | -24.29% | -22.44% | -18.06% | -17.60% | -17.14% | -47.46% | -40.81% |
December 31, 2024 calculation
Operating ROA = Operating income (ttm) ÷ Total assets
= $-536,248K ÷ $1,401,670K
= -38.26%
Operating return on assets (Operating ROA) for Cytokinetics Inc has shown significant fluctuations over the past few quarters. The trend indicates that the company's operating performance relative to its total assets has been negative, with values ranging from -17.14% to -66.95% from September 30, 2020, to September 30, 2023.
The Operating ROA deteriorated sharply from an already weak position in the recent quarters, falling to -61.62% on March 31, 2024. This downward trend suggests that the company's ability to generate operating income from its assets has weakened substantially.
The consistent negative Operating ROA may signify inefficiencies in the company's operations relative to the size of its asset base, indicating potential issues in cost management, revenue generation, or asset utilization. It is crucial for Cytokinetics Inc to address these operational challenges to improve its overall financial performance and enhance shareholder value.
Peer comparison
Dec 31, 2024